Trade NextCure, Inc. - NXTC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.56 |
| Open | 1.53 |
| 1-Year Change | -10% |
| Day's Range | 1.52 - 1.66 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 25, 2024 | 1.55 | 0.00 | 0.00% | 1.55 | 1.61 | 1.54 |
| Jul 24, 2024 | 1.58 | 0.04 | 2.60% | 1.54 | 1.65 | 1.53 |
| Jul 23, 2024 | 1.56 | 0.04 | 2.63% | 1.52 | 1.68 | 1.51 |
| Jul 22, 2024 | 1.58 | -0.06 | -3.66% | 1.64 | 1.70 | 1.55 |
| Jul 19, 2024 | 1.68 | 0.04 | 2.44% | 1.64 | 1.73 | 1.53 |
| Jul 18, 2024 | 1.66 | 0.01 | 0.61% | 1.65 | 1.72 | 1.62 |
| Jul 17, 2024 | 1.73 | 0.05 | 2.98% | 1.68 | 1.74 | 1.62 |
| Jul 16, 2024 | 1.73 | 0.07 | 4.22% | 1.66 | 1.75 | 1.55 |
| Jul 15, 2024 | 1.65 | 0.02 | 1.23% | 1.63 | 1.68 | 1.58 |
| Jul 12, 2024 | 1.59 | 0.05 | 3.25% | 1.54 | 1.60 | 1.51 |
| Jul 11, 2024 | 1.57 | -0.03 | -1.88% | 1.60 | 1.66 | 1.56 |
| Jul 10, 2024 | 1.56 | 0.04 | 2.63% | 1.52 | 1.58 | 1.50 |
| Jul 9, 2024 | 1.57 | 0.05 | 3.29% | 1.52 | 1.68 | 1.51 |
| Jul 8, 2024 | 1.51 | 0.08 | 5.59% | 1.43 | 1.54 | 1.43 |
| Jul 5, 2024 | 1.45 | -0.10 | -6.45% | 1.55 | 1.62 | 1.44 |
| Jul 3, 2024 | 1.55 | 0.06 | 4.03% | 1.49 | 1.57 | 1.49 |
| Jul 2, 2024 | 1.47 | 0.04 | 2.80% | 1.43 | 1.48 | 1.34 |
| Jul 1, 2024 | 1.46 | -0.12 | -7.59% | 1.58 | 1.62 | 1.42 |
| Jun 28, 2024 | 1.58 | -0.05 | -3.07% | 1.63 | 1.64 | 1.56 |
| Jun 27, 2024 | 1.60 | 0.04 | 2.56% | 1.56 | 1.64 | 1.56 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
NextCure, Inc. Company profile
About NextCure Inc
Nextcure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its product candidates include NC318, NC410, and NC762. Its lead product candidate NC318, is an immunomedicine targeting an immunomodulatory receptor called Siglec-15 (S15). The Company is evaluating NC318 for the treatment of metastatic solid tumors, including head and neck squamous cell carcinoma (HNSCC) and triple-negative breast cancer (TNBC). It is conducting Phase II investigator-initiated clinical trial of NC318 in combination with pembrolizumab in patients with non-small cell lung cancer (NSCLC). Its second product candidate NC410, is an immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor1. Its NC762, is a monoclonal antibody targeting an immunomodulatory molecule called human B7 homolog 4 protein (B7-H4).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, NextCure Inc revenues decreased from $22.4M to $0K. Net loss increased 90% to $69.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Other income, net decrease of 70% to $1.4M (income), Research and development - Balancing val increase of 6% to $46.1M (expense).
| Industry: | Bio Therapeutic Drugs |
9000 Virginia Manor Rd Ste 200
BELTSVILLE
MARYLAND 20705-4214
US
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com